Results 41 to 50 of about 125 (92)

Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA

Современная ревматология, 2023
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work ...
T. V. Dubinina, A. B. Demina, E. M. Agafonova, Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova   +25 more
doaj   +1 more source

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

Vestnik Dermatologii i Venerologii, 2019
Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation,
A. A. Kubanov, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, E. V. Sokolovskiy, M. M. Kokhan, A. V. Artemyeva, E V. Chernyaeva, R. A. Ivanov   +8 more
doaj   +1 more source

OP0142 NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL [PDF]

Annals of the Rheumatic Diseases, 2021
Background: The presence of sacroiliitis in patients (pts) with ankylosing spondylitis (AS) on imaging can be established both by sacroiliac joint (SIJ) X-ray or MRI. Active sacroiliitis on MRI as defined by ASAS is predictor of good treatment response to biological disease modifying anti-rheumatic drugs [1, 2].
I. Gaydukova, V. Mazurov, S. Erdes, T. Dubinina, A. Kundzer, N. Soroka, A. Eremeeva   +6 more
openaire   +1 more source

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Современная ревматология, 2020
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan   +24 more
doaj   +1 more source

OP0232 NETAKIMAB REDUCES THE DISEASE ACTIVITY OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. RESULTS OF ASTERA STUDY [PDF]

Annals of the Rheumatic Diseases, 2019
Background Efficacy and safety of netakimab (NTK), a humanized anti-IL17A antibody, was established in phase 2 clinical trials in patients (pts) with radiographic axial spondyloarthritis (r-axSpA)1 and psoriasis2. Objectives The abstract presents 16-week data from ongoing ASTERA study (NCT03447704) in pts with active r-axSpA.
Inna Gaydukova, V Mazurov, Shandor Erdes, Tatiana Dubinina, Olga Nesmeyanova, Elena Ilivanova, Alena Kundzer, Nikolaj Soroka, Aleksander Kastanayan, Tatyana Povarova, Elena Zhugrova, Tatyana Plaksina, Pavel Shesternya, Tatyana Kropotina, Olga Antipova, Elena Smolyarchuk, Oksana Tciupa, Diana Abdulganieva, Diana Kretchikova, Ivan Gordeev, Vadim Tyrenko, Aleksandra Strelkova, Anna Eremeeva, Ekaterina Chernyaeva, Roman Ivanov   +24 more
openaire   +1 more source

Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

Vestnik Dermatologii i Venerologii, 2019
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimate ...
A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, V. R. Khairutdinov, M. M. Kokhan, A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva, R. A. Ivanov   +8 more
doaj   +1 more source

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Научно-практическая ревматология, 2020
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods.
V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva   +24 more
doaj   +1 more source

Experience with the use of glucocorticoids and netakimab in the treatment of patients with COVID-19 in outpatient settings

Clinical Medicine (Russian Journal), 2020
Goal.Tostudythe efficacyand safety of therapy with netakimab (NTK) and the complex drug — betamethasone dipropionate +betamesone phosphate (B) in patients with COVID-19 in outpatient settings. Materialand methods.A retrospective analysisof the treatment of 12 patients with severe new coronavirus infection who received therapy was performed simultaneously
R. Е. Pavlov, S. V. Tsarenko, A. V. Sekinaeva, P. N. Rybin, M. V. Nagibinа, E. V. Soshnikovа, M. S. Klimova   +6 more
openaire   +2 more sources

Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS

Вопросы современной педиатрии
Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Nikolay N. Murashkin, Andrey L. Bakulev, Pavel V. Gorodnichev, Denis V. Zaslavskiy, Oleg R. Ziganshin, Muza M. Kokhan, Sergey V. Koshkin, Anna A. Maksimova, Yulia S. Kovaleva, Tatiana E. Pak, Olga A. Sidorenko, Dmitriy B. Sonin, Bulat V. Khalilov, Alkes A. Khotko, Antonina V. Artem’eva, Anna V. Eremeeva, Arina V. Zinkina, Yulia N. Lin’kova, Elena S. Kolosova, Anton A. Lutskiy, Ekaterina A. Fokina   +20 more
doaj   +1 more source

Efficacy and safety of biologics for the treatment of ankylosing spondylitis: systematic literature review and network meta-analysis of treatments registered in the Russian Federation

Научно-практическая ревматология, 2021
The aim of the study was to evaluate the comparative efficacy and safety of biologics registered and reimbursed in the Russian healthcare system for the treatment of adult patients with active ankylosing spondylitis.Material and methods.
T. V. Dubinina, I. Z. Gaydukova, V. D. Sokolova, V. V. Mladov, D. G. Tolkacheva   +4 more
doaj   +1 more source